Navigation Links
The Quigley Corporation Announces Sale of Its Health and Wellness Segment
Date:3/3/2008

DOYLESTOWN, Pa., March 3 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY) today announced that on February 29, 2008 it completed the sale of it wholly owned subsidiary, Darius International Inc. ("Darius"), which markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. to InnerLight Holdings, Inc., whose major shareholder is Mr. Kevin P. Brogan, the current president of Darius.

The terms of the agreement include a cash purchase price of $1 million by InnerLight Holdings, Inc. for the stock of Darius and its subsidiaries without guarantees, warranties or indemnifications. The unaudited net book value of Darius at December 31, 2007 and 2006 approximate $124,000 and $2.4 million, respectively. Darius' net sales for 2007 and 2006 approximate $11.2 million and $15.3 million, respectively with a net loss for 2007 and 2006 approximating $600,000 and $1.2 million, respectively.

Darius is a direct selling organization that constituted the Health and Wellness segment of the Company, which was formed by The Quigley Corporation in 2000 to introduce new products to the marketplace through a network of independent distributor representatives.

Over the last few years, net sales of this wholly owned subsidiary have declined and profits have turned to losses for this Health and Wellness segment reflecting the continued reduction in the number of active independent distributor representatives, and the effects of ongoing litigation with the sponsor of its product line.

As the Company continues to review its current structure, ownership of this subsidiary, constituting the Health and Wellness segment, is no longer a benefit for the Company since losses by this segment have been a dr
'/>"/>

SOURCE The Quigley Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
2. Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date
3. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
4. National Atlantic Holdings Corporation to Report Fourth Quarter and Year-End 2007 Earnings on March 17, 2008
5. Linkwell Corporations Skin Disinfectant Product Chosen for 2008 Beijing Olympic Games
6. Partners Center for Connected Health and EMC Corporation Launch New Web-Based Remote Monitoring Program to Help Employees Fight Hypertension
7. China Bionanometer Industries Corporation Announces New Products for China
8. Centene Corporation Unveils Winners of the 2008 Physician Summit Award
9. Dialysis Corporation of America Announces its Newest Center Opening in South Carolina
10. Harris Corporation Demonstrates Digital Signage(TM) Solutions for Dynamic, Rapid Communications within Healthcare Enterprises
11. Harris Corporation Unveils Broadcast-Style Multiviewers for Real-Time Multi- Screen Access to Medical Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...ANTON, Calif., July 25 /PRNewswire-FirstCall/ -- T...r in device-based mechanical,circulatory support t...ts,today announced that it will report its operat...onths of fiscal 2008 on Thursday, July 31., The c...financial,results and operating activities to all ...
(Date:7/25/2008)...rtain cleaning products reduces lung function, inc... FRIDAY, July 25 (HealthDay News) -- A clean, fres...h, depending on what type of cleaning and air fres...ests that exposure to cleaning products or air fre...mpound (VOC) called 1,4 dicholorobenzene (1,4 DCB)...
(Date:7/25/2008)...OK, Ill. July 25, 2008 The American Society for...elines on the role of endoscopy in the bariatric s...n the United States and the success in surgical in... of weight-loss surgeries performed in the U.S., f...nes discuss endoscopy in the preoperative patient ...
(Date:7/25/2008)...S, July 25 /PRNewswire/ -- BeaconEquity.com announ...ing news today., Investors can view all of the da...aconEquity.com/m , Today,s Trade Alerts include: ...Brook Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaM...R ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis I...
Breaking Medicine News(10 mins):Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3
...lic supplements may not help reduce cholesterol or...lic consumed, says a new study//. Several earlier...ower cholesterol. However, researchers at Stanford...different garlic supplements on nearly 200 adults ...
...vehicles whiz past E.M. Bypass on the city's easte...left indicates the Kolkata Municipal Corporation's... Animals (PFA). It is here that the adage every ...ling pound aims to restore the mental and physical...
...earchers in Philadelphia have found a ground break...brought them to be able to trigger the Epstein-Bar...ntify patients whose infections can then be manipu...at this strategy could actually offer a novel way ...
... annual report for the year 2006 of the Internatio...to UN), suggests that abuse of prescriptions drugs...obe. The abuse of prescription drugs surpasses ...asy, cocaine and heroine in parts of Europe, Afric...
Other Medicine News:Health News:An Anti-rabies Campaign With Bite 2Health News:An Anti-rabies Campaign With Bite 3Health News:Philadelphia Researchers Found A Novel Way To Fight Several Kind of Cancers 2Health News:Philadelphia Researchers Found A Novel Way To Fight Several Kind of Cancers 3
(Date:7/24/2008)...Support Prognostic Value of Circulating Tumor Cell...rnational, prospective,clinical trial found the nu... indicator of progression-free and overall surviva...ording to a report published in the July 1,issue o...onducted in the US, the Netherlands, and the Unite...
(Date:7/24/2008)...AIN VIEW, Calif., July 24 /...nounced today that it has initiated,its second Pha...ine).,AZ-004 is an inhalation product candidate be... in patients with schizophrenia or bipolar disorde...and rapid pharmacokinetic,(PK) properties resultin...
(Date:7/24/2008)...New JIT Enrollment Program Speeds Oncology Patient...ech, Inc., a Research Management,Organization (RMO...,companies to provide research and site management...-in-Time (JIT) enrollment strategy. The new,trials...ular Non-Hodgkin,s,Lymphoma, Metastatic Breast Can...
(Date:7/24/2008)...A ANTIPOLIS, France, July 24 /PRNewswire-FirstCall...ced the top-line results from the 52-week,open lab...he completion of,the 301 phase 3 study for naproxc...ndings and efficacy was maintained for the one-yea...ts, global assessment scale. In,addition, the resu...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 1Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 5Citrate appears to control buckyball clumping but environmental concerns remain 4478 1Citrate appears to control buckyball clumping but environmental concerns remain 4478 2Citrate appears to control buckyball clumping but environmental concerns remain 4478 3Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 1Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 2Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 3Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 1Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 2
...NGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM)...tion, may be an,effective treatment for moderate-t...going double-blind, placebo controlled Phase II,st...nduced good,clinical remissions and improved patie...researchers from Hebrew University-Hadassah,Medica...
... results report no new stent thrombosis after two ...s., and BARCELONA, Spain, May 22, 2007,/PRNewswire...,announced four-year follow-up data from its TAXUS... safety and efficacy benefits,associated with a mo...(TM) paclitaxel-eluting stent system -- which is n...
Other Medicine Technology:Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 2Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 3Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3
Shafts angled 8 mm from tip to bend with smooth jaws. Flat, cross action handle with holes and dull finish.
Designed to accurately fold most flexible intraocular lens for ease of grasping with the folding instruments. The notched jaws align the implant and position it for a precise fold. Ideal for lens dia
Biconvex jaw design. 40 degree angled shafts. Tip to angle length: 7.5 mm. Locking handle. Manufacturing in titanium.
45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium.
Medicine Products: